Boston Scientific reports Q2 adjusted EPS 53c, consensus 49c

Reports Q2 revenue $3.6B, consensus $3.5B. “We had another quarter of excellent results fueled by our innovative portfolio, strong commercial execution and the high performance of our global team,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “We are excited about our long-term outlook and robust pipeline of unique innovations to address unmet patient needs.”